Participants 88 145 6
treatment-experienced hepatitis C virus-infected patients
Participants 701 816 5
pegylated IFN/RBV treatment-experienced Japanese patients with hepatitis C virus subtype 1b or genotype 2 infection
Participants 818 1114 11
Patients without cirrhosis (aged 18-75 years) with subtype 1b infection received ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg for 12 or 24 weeks; patients with genotype 2 infection received ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg for 12 week
Participants 1264 1288 5
One hundred ten patients
Participants 1782 1866 4
s difficult-to-treat population of patients in whom prior pegylated IFN/RBV had fail
Participants 1979 2048 5
g Japanese patients with hepatitis C virus genotype 1b or 2a infectio
